Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro
Article 2021 en
Authors
MM
Martina Morokutti-Kurz
MF
Maria Fröba
PG
Philipp Graf
Abstract
1 min read
In the absence of a vaccine and other effective prophylactic or therapeutic countermeasures the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) remains a significant public health threat. Attachment and entry of coronaviruses including SARS-CoV-2 is mainly mediated by the spike glycoprotein. Here, we show that iota-carrageenan can inhibit the cell entry of the SARS-CoV-2 spike pseudotyped lentivirus in a dose dependent manner. SARS-CoV-2 spike pseudotyped lentivirus particles were efficiently neutralized with an IC50 value of 2.6 μg/ml iota-carrageenan. Experiments with patient isolated wild type SARS-CoV-2 virus showed an inhibition of replication in a similar range. In vitro data on iota-carrageenan against various Rhino- and endemic Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction of severity and duration of symptoms of common cold caused by various respiratory viruses. Accordingly, our in vitro data on SARS-CoV-2 spike pseudotyped lentivirus and replication competent SARS-CoV-2 suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections.
Christian Setz, Maximilian Große, Maria Fröba, Janina Auth, Pia Rauch, Alexandra Herrmann, Arne Cordsmeier, Armin Ensser, Michael Schindler, Martina Morokutti-Kurz, Philipp Graf, Benedikt Engel, Eva Prieschl‐Grassauer, Andreas Grassauer, Ulrich Sigmar Schubert
Maria Fröba, Maximilian Große, Christian Setz, Pia Rauch, Janina Auth, Lucas Spanaus, Jan Münch, Natalia Ruétalo, Michael Schindler, Martina Morokutti-Kurz, Philipp Graf, Eva Prieschl‐Grassauer, Andreas Grassauer, Ulrich Sigmar Schubert
Discussion(0)
No comments yet. Be the first to comment.